npj precision oncology impact factor bioxbio

Cancer Discov. Diagonalizing selfadjoint operator on core domain. The mean value of all patients is shown in the red curve. contracts here. Context is everything: aneuploidy in cancer. Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D. & Agostinis, P. Inducers of immunogenic cancer cell death. CAS Get what matters in cancer research, free to your inbox weekly. Cancer Res. 193, 839846 (2001). 2015)120. Finally, autonomous type I IFN increases CXCL10 secretion and T-cell recruitment, thus exerting antitumor effects40,41. Genomic investigation of co-targeting tumor immune - Nature How can the specificity of ICD inducers be improved? Krysko, D. V. et al. JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. ), National Key Research and Development Program (2019YFC1316000 to T.L. Sorted by: 2. npj Precision Oncology has a 2-year impact factor of 10.092 (2021), article downloads of 431,304 (2021) and 5 days from submission to the first editorial decision (2021). Nature 531, 4752 (2016). Compared with normal tissue, the expression level of MET was downregulated in BRCA, LAML, and LGG and upregulated in 20 types of cancers including CESC, COAD, and PAAD (Fig. npj Precision Oncology - Vrije Universiteit Amsterdam 3). USA 115, E10119E10126 (2018). Hieronymus, H. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. For all such questions, go to Journal Citation Reports (JCR) and search for the impact factor. 8a), which resulted in AS=0 for nearly half of the samples (Supplementary Fig. For example, MUC1, a cell surface TIME factor found on epithelial cells, is found associated with HDGF where they share 26 variants in 769 patient samples. Cell 141, 5267 (2010). These results suggested that the induction of tumor ICD offers promising prospects for the development of combination immune therapies to broadly and effectively reshape TIME and ultimately reinvigorate the immune system against tumors. We hence reasoned that an arbitrary threshold could never be optimal for all datasets and searched for an unbiased approach for threshold calling. https://doi.org/10.1126/science.aaf8399 (2017). Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. We are always looking for inspiration, feedback, and collaborators. Genomic analyses identify molecular subtypes of pancreatic cancer. An international, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications to clinical medicine. The patient TMB, AS, and FGA values were binarized into score-high versus score-low groups in a cancer-type-specific manner. Thank you for visiting nature.com. Sansregret, L. & Swanton, C. The role of aneuploidy in cancer evolution. Nat. We defined the gene mutation frequency in a group of patients as the fraction of patients with mutations in the gene of interest. Contemp. To obtain In this study, cBioPortal was used for visualization and comparison of genetic alterations of ICPs and TIME factors in pancreatic cancer, as well as alteration-associated contribution to multiple survivors of pancreatic cancer patients. There are a number of parameters that may affect the optimal cutoff, e.g., cancer type, tumor purity, and the platform used for CNA calling (e.g., whole-exome sequencing, single nucleotide polymorphism arrays, and shallow whole genome sequencing)10,11,12,13,14. In addition to the expression level of ICPs, TIME-related markers should also be further considered for a better outcome and safety. Ma, Y., Galluzzi, L., Zitvogel, L. & Kroemer, G. Autophagy and cellular immune responses. This is a lower-ranking index, and if the journal has only just been indexed by ESCI, it certainly hasn't been indexed by SCI and SSCI (which are the indices that yields an impact factor). Sharma, P., Hu-Lieskovan, S., Wargo, J. Previous reports associated PD-L1 overexpression with poor prognosis in various cancers55,56,57; however, contradictory results were reported for breast cancer, HNSC, renal cell carcinoma, and upper tract urothelial carcinoma58,59,60,61. ICB is not sufficient for cancer immunotherapy. Google Scholar. Biol. The ISSN of this journal is N/A. Ben-David, U. Firstly, MET (HGF receptor, traditional receptor tyrosine kinase but with a novel regulatory function in cancer immunity31,32,33) was chosen as a representative TIME factor. Indeed, pharmacological or genetic suppression of ICD largely diminishes the curative effects of anthracyclines-based immunogenic chemotherapy25,39,40,93,94,95,96,97. This included direct (physical) binding and indirect (functional) association, originating from interactions aggregated from primary databases. 47, W556W560 (2019). T.-G.C., Y.C., and E.D.S. Pembrolizumab for the treatment of non-small-cell lung cancer. Electronic address, a. a. d. h. e. & Cancer Genome Atlas Research, N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Am. We hypothesized that CNA calling cutoff |log2 copy ratio|>0.1 is a too low cutoff, which introduced noise in calculating patient AS, and thus dampened its predictive power of survival following immunotherapy. T.-G.C. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. So far, to neutralize their immunosuppressive effects and maximize the immunostimulatory functions of anticancer drugs, the chemotherapeutic drug gemcitabine has been combined with ipilimumab in preclinical models107. Given the complexity of the interaction between TIME factors and ICPs and their enormous influence on the tumor immune suppressive microenvironment, combination therapy might be indicated to efficiently reinvigorate the immune system against tumors. Oncol. Journal's Impact IFHot 2 Year IF 3 Year IF4 Year IF5 Year IFReal-Time IFIF Prediction Acceptance RateUpdated Review SpeedUpdated Advanced Factors Cite Score Google Scholar Metrics H-Index Quartile Ranking Self-Citation Ratio Source Normalized Impact per Paper Adalsteinsson, V. A. et al. This strategy can, at least in principle, not only directly (albeit only partially) kill cancer cells and stimulate short-term immune clearance of the remaining cells, it can also maintain long-lasting immune memory to prevent a recurrence. 6. Wald P values for HRs of ASEP in individual cancer types are displayed at the right side of the plot. Here, our results revealed the prognostic significance of TIME factors in multiple cancers and their close relationship with ICPs, implicating tumors use both ICPs and TIME factors to escape from immune surveillance. The cellular and molecular basis of translational immunometabolism. JAMA Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology.JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.. Journal Frequency and Access. Apetoh, L. et al. To learn more about how these trackers help us Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Med. The combined scores indicating the confidence in the interaction rank from 0 to 1, with 1 being the highest possible confidence. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Nat. Stovgaard, E. S., Dyhl-Polk, A., Roslind, A., Balslev, E. & Nielsen, D. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Natl Acad. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. ISSN: 0030-2414. Impact factor data has a strong influence on the scientific community, affecting decisions on where to publish, whom to promote or hire, the success of grant applications, and even salary bonuses. This community is not edited and does not necessarily reflect the views of Springer Nature (of which Nature Portfolio is part). Oncoimmunology 5, e1149673 (2016). a Landscape of genetic alterations of ICPs and TIME factors in pancreatic cancer. Clin. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Thank you for visiting nature.com. Differential expression analysis showed that compared with normal tissue, the expression levels of PD-L1 were significantly upregulated in DLBC and THYM and downregulated in LUAD, LUSC, and USC (Fig. However, although ICB is frontline therapy for many cancers, increasing numbers of studies have shown that the positive response rate from patients receiving drugs that target ICPs remains quite low in several specific malignancies. Taken together, these results suggest that the elbow method, a simple and non-parametric method, is robust and superior to some arbitrarily chosen cutoffs (e.g., the 0.1 cutoff used in ref. Nucleic Acids Res. 47, D607D613 (2019). Do npj and Nature-branded journals have the same reputation such that I can say I published "in a Nature journal" after publishing in npj? Dozens of clinical trials have demonstrated the ability of ICP inhibitors to achieve durable objective responses in advanced patients9,10,13,54. Oncol. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in To obtain Proc. Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China, Xing Huang,Tianyu Tang,Gang Zhang,Zhengtao Hong,Jian Xu,Dipesh Kumar Yadav,Xueli Bai&Tingbo Liang, Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China, Innovation Center for the Study of Pancreatic Diseases, Zhejiang Province, Hangzhou, 310003, Zhejiang, China, You can also search for this author in Nat. Check top authors, submission guidelines, Acceptance Rate, Review Speed, Scope, Publication Fees, Submission Guidelines at one place. PubMed Rev. Nature Reviews Gastroenterology & Hepatology, PRECISION ENGINEERING-JOURNAL OF THE INTERNATIONAL SOCIETIES FOR PRECISION ENGINEERING AND NANOTECHN, Circulation-Genomic and Precision Medicine, Expert Review of Precision Medicine and Drug Development, International Journal of Precision Engineering and Manufacturing-Green Technology. Google Scholar. J. Clin. SCI was established in 1900 to the current. Given that ICPs can serve as a part rather than the opposite side of TIME factors, it may not be necessary to differentiate between ICPs and TIME factors in the future, but rather, they should be targeted together. 1). 7, 54 (2023). You are using a browser version with limited support for CSS. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. The latest impact factor of npj Precision Oncology and all the other SCI journals was released on 30th June 2022 by Clarivate. Eng. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Nature Portfolio. New functions for the matrix metalloproteinases in cancer progression. N. Engl. Front. Tomczak, K., Czerwinska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. 15, 95111 (2018). d Univariable KaplanMeier survival analysis and multivariable survival analysis using Cox proportional hazards regression of overall survival with AS calculated using cancer-type-specific elbow-point-based CNA calling cutoff (ASEP; binned at the 30th percentile), TMB (binned at the 80th percentile), and ICB drug class. mean? The prognostic and therapeutic value of PD-L1 in glioma. Nat. Nature 515, 563567 (2014). Cell 161, 205214 (2015). Although various studies have shown that high tumor mutation burden (TMB) may predict immunotherapy response, at least in some cancer types1,2, more precise identification of patients that are likely to respond to cancer immunotherapy is still a challenging unmet clinical need. The journal defines precision oncology as cancer diagnosis, prognosis, prevention and/or treatment tailored . Nature 553, 9195 (2018). Bioinformatics 34, 20042011 (2018). 24, 319333 (2013). SCI-indexed journals are indexed by SCI and SSCI. The Journal Impact Factor is defined as citations to the journal in the JCR year to items published in the previous two years, divided by the total number of scholarly items, also known as citable items, (these comprise articles and reviews) published in the journal in the previous two years. Similarly, the optimal percentiles to binarize the AS0.1, FGA0.1, and FGA0.2 scores are 50th, 40th, and 50th, respectively (Fig. Although direct TIME targeting still remains difficult, ICD inducers may effectively help to reshape TIME and are thus suitable for combination with ICPs inhibitors. e Correlation of TIME factors and effector T-cell signatures in pancreatic cancer. Nature 463, 899905 (2010). Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. case 1. Oncoimmunology 4, e1008866 (2015). reported that the tumor aneuploidy score (AS), defined as the fraction of chromosome arms with arm-level CNAs in a sample, which was called using a loose cutoff of |log2 copy ratio|>0.1, is significantly predictive of survival following immunotherapy in low-TMB patients, but not in high-TMB patients, in a pan-cancer analysis6. The ICPs investigated in this study included the most well-established PD-L1, PD-L2, CD80, CD86, VTCN1, C10orf54, HHLA2, TNFRSF14, CD155, CD112, CD200, LGALS9, ICOSL, CD137L, CD252, CD70, GITRL, and CD48111. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. In addition, we also tested using another method to determine the cutoff, testing a Gaussian mixture model. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Pol, J. et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Gentili, M. et al. Genet. Google Scholar. It says on the website that the journal has been indexed by ESCI (Emerging Science Citation Index). Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Clin. Trial Watch: chemotherapy with immunogenic cell death inducers. Nat. npj Precision Oncology has been in operation since 2017 till date. As a redox signaling protein, Ref-1/APE1 enhances the transcriptional activity of STAT3, HIF-1, nuclear factor kappa B, and other transcription factors to promote growth, . and T.T. 53, 761761 (2021). Vacchelli, E. et al. Only Open Access Journals Only SciELO Journals Only WoS Journals PubMed Central USA 100, 53365341 (2003). The impact score (IS), also denoted as Journal impact score (JIS), of an academic journal is a measure of the . The latest impact factors list will release in june 2023. Urol. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Identifying patients that are likely to respond to cancer immunotherapy is an important, yet highly challenging clinical need. 86, 8190 (2018). And, my PhD publication dilemma regarding it. Immunotherapy 9, 681692 (2017). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. Pharm. Cancer Res. What is an impact score? Provided by the Springer Nature SharedIt content-sharing initiative, npj Precision Oncology (npj Precis. Paired Wilcoxon test P values are displayed. Oncoimmunology 3, e27878 (2014). 2a) and disease-free survival (DFS) (Fig. Nat. Cancer immunology. eLife 7, https://doi.org/10.7554/eLife.37294 (2018). & Su, Y. X. Here, the HR denotes the relative risk of the AS0.1-high individuals compared to the AS0.1-low set as the reference. The high-throughput database provided valuable information toward a deeper understanding of the underlying mechanism of the anticancer efficacy of the immune system. Hino, R. et al. In fact, ICB represents a specific treatment category that has seen some of the highest FDA and regulatory approvals across many cancer types within a relatively short timein the past over 5 years based on large randomized trials proving survival benefit even as single agents, whether biomarker-driven or not. 202, 16911701 (2005). GEPIA generates the KaplanMeier DFS map comparing the groups with different expression levels of TIME factors in multiple cancer types (TCGA tumor). 17, 97111 (2017). 9g), and P2RX7 (Fig. 45, 11131120 (2013). JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 16. Therefore, it is necessary to develop a more effective and safe anticancer immunotherapeutic strategy. J. Galluzzi, L., Bravo-San Pedro, J. M., Demaria, S., Formenti, S. C. & Kroemer, G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Aneuploidy scores were called using ASCETS at https://github.com/beroukhim-lab/ascets and values for each sample are provided in the GitHub repository at https://github.com/rootchang/Aneuploidy-FGA-ICB. Otherwise please guide the asker and vote to reopen the question if appropriate. 36, 17141768 (2018). Each dot represents the individual expression of a distinct tumor or normal sample. Breast Cancer Res. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. performed the literature search, bioinformatics analysis, data collection, analysis, and interpretation, as well as figure preparation, with the kind assistance of G.Z. IOP Conf. J. e Pan-cancer KaplanMeier analysis of AS0.2 binned at the 60th percentile and AS0.1 binned at the 50th percentile in the Samstein et al.s cohort. 7c), and disease-specific survival (DSS) (Fig. 2). Datasets and metadata supporting the article: Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Genet. This result testifies that the AS0.1 indeed mis-classifies a number of patients as a result of the loose CNA calling cutoff used. Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Since both ICPs and TIME factors are critical for the prognosis of cancer patients, the next step investigated the existence of potential interplays between ICPs and TIME factors. Springer Nature makes no representations, warranties or guarantees, whether express or implied, that the content on this community is accurate, complete or up to date, and to the fullest extent permitted by law all liability is excluded. The left axis depicts the number of papers published in years X-1 and X-2, and . Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. Cell Rep. 19, 11891201 (2017). 5, 122 (2020). The influence of TIME factors was investigated through differential expression analysis and survival analysis using GEPIA. rev2023.6.2.43474. However, FGA0.2 did not predict worse survival for high FGA0.2 in bladder cancer in this cohort as what in the Samstein et al.s cohort (HR=0.79, P=0.39; Fig. Med. CAS This study was supported by grants from the National Natural Science Foundation of China (31970696 and 81502975 to X.H., and 81830089 to T.L. International Scientific Journal & Country Ranking. As a result, FGA0.2 had significant KaplanMeier univariable HRs for pan-cancer (HR=1.22, P=0.003) and in renal cell carcinoma (HR=2.07, P=0.019) and melanoma (HR=1.75, P=0.018). Comparison of HRs using AS0.1 or AS0.2 or FGA0.1 or FGA0.2 in a multivariate Cox model with TMB and ICB drug class. J. Clin. Spearman correlation analysis was used to analyze the pair-wise gene expression correlations between ICPs and TIME factors, and results with p value <0.01 were selected. npj Precision Oncology (npj Precis. This research was supported in part by the NIH Intramural Research Program, National Cancer Institute. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Google Scholar. Intrigued by these potentially clinically impactful findings, we set out to explore several related fundamental questions: (1) Does the choice of cutoff during CNA calling influence the predictive power? Cancer Cell 32, 185203.e113 (2017). Appl. Kroemer, G., Galluzzi, L., Kepp, O. 9a), LRP1 (Fig. Edited. N. Engl. Vaccines. The estimated sample size for non-small cell lung cancer in the Samstein et al.s cohort to achieve P<0.05 is about 1600 (Supplementary Table 1). Tian-Gen Chang or Eytan Ruppin. The genomic alterations of TIME factors showed general co-occurrence rather than mutual exclusivity with ICPs. This milestone achievement is a collaboration between one of the world's top research journals (Nature) and The Hormel Institute, a University of Minnesota . The time period covers overall patient survival status. To further clarify the significance of ICP targeting, this study first chose PD-L1 as an example of a critical target of ICB to conduct globally prognostic analyses via gene expression profiling interactive analysis (GEPIA). How can the suppressed ICD be restored? It also indicated the feasibility of combined treatment to boost a controllable anticancer immune response to overcome immunotherapeutic resistance in clinical applications. 3).
Keysight Infiniivision 2000 X-series Oscilloscopes Programmer's Guide, 2010 Kubota M7040 Specs, Maheshwari Saree Shop In Indore, Robocash Customer Care Number Near Paris, Easa Approved Maintenance Organisations, Articles N